Reuters logo
BRIEF-Alvogen unit confirms ANDA filing and patent challenge for generic Revlimid
September 11, 2017 / 2:37 PM / 13 days ago

BRIEF-Alvogen unit confirms ANDA filing and patent challenge for generic Revlimid

Sept 11 (Reuters) - Lotus Pharmaceuticals:

* Alvogen subsidiary confirms ANDA filing and patent challenge for generic Revlimid

* Alvogen’s unit Lotus Pharmaceuticals announced that Celgene filed suit on Sept 6, in U.S. District Court for district of New Jersey​

* ‍Lotus says Celgene’s lawsuit resulted in stay of FDA approval of Lotus’ ANDA for up to 30 months from date plaintiffs, Celgene, got notice of Lotus’ ANDA filing​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below